

Qingbin Cui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8407416/publications.pdf>

Version: 2024-02-01

33
papers

1,364
citations

430874

18
h-index

434195

31
g-index

35
all docs

35
docs citations

35
times ranked

1685
citing authors

#	ARTICLE	IF	CITATIONS
1	Modulating ROS to overcome multidrug resistance in cancer. <i>Drug Resistance Updates</i> , 2018, 41, 1-25.	14.4	420
2	Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. <i>Drug Resistance Updates</i> , 2020, 48, 100663.	14.4	180
3	Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance. <i>Drug Resistance Updates</i> , 2021, 54, 100743.	14.4	107
4	Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. <i>Cancer Letters</i> , 2018, 421, 186-198.	7.2	96
5	Targeting cancer cell mitochondria as a therapeutic approach: recent updates. <i>Future Medicinal Chemistry</i> , 2017, 9, 929-949.	2.3	64
6	<i>N</i> -Benzylthiocarbamate Salts as Sulfur Sources to Access Tricyclic Thioheterocycles Mediated by Copper Species. <i>Advanced Synthesis and Catalysis</i> , 2016, 358, 2733-2738.	4.3	40
7	The targeting of non-coding RNAs by curcumin: Facts and hopes for cancer therapy (Review). <i>Oncology Reports</i> , 2019, 42, 20-34.	2.6	38
8	Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. <i>Cancers</i> , 2020, 12, 466.	3.7	37
9	Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible. <i>Future Medicinal Chemistry</i> , 2019, 11, 323-336.	2.3	31
10	Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 955.	2.8	31
11	Repositioning Lidocaine as an Anticancer Drug: The Role Beyond Anesthesia. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 565.	3.7	30
12	A Novel Danshensu Derivative Prevents Cardiac Dysfunction and Improves the Chemotherapeutic Efficacy of Doxorubicin in Breast Cancer Cells. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 94-105.	2.6	29
13	Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study. <i>Frontiers in Oncology</i> , 2019, 9, 514.	2.8	29
14	Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells. <i>Frontiers in Oncology</i> , 2019, 9, 313.	2.8	28
15	Design, Synthesis, and Preliminary Cardioprotective Effect Evaluation of Danshensu Derivatives. <i>Chemical Biology and Drug Design</i> , 2014, 84, 282-291.	3.2	24
16	Modulating the function of ABCB1: <i>in vitro</i> and <i>in vivo</i> characterization of sitravatinib, a tyrosine kinase inhibitor. <i>Cancer Communications</i> , 2020, 40, 285-300.	9.2	24
17	Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4095.	4.1	19
18	Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 601400.	3.7	18

#	ARTICLE	IF	CITATIONS
19	Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter. <i>Frontiers in Oncology</i> , 2020, 10, 574861.	2.8	16
20	Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 228.	2.8	15
21	eIF3i regulation of protein synthesis, cell proliferation, cell cycle progression, and tumorigenesis. <i>Cancer Letters</i> , 2021, 500, 11-20.	7.2	14
22	NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance. <i>Frontiers in Oncology</i> , 2020, 10, 1219.	2.8	11
23	The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2463.	4.1	10
24	A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 65, 116761.	3.0	8
25	Insights on the structure–function relationship of human multidrug resistance protein 7 (MRP7/ABCC10) from molecular dynamics simulations and docking studies. <i>MedComm</i> , 2021, 2, 221-235.	7.2	7
26	Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells. <i>Frontiers in Pharmacology</i> , 2022, 13, 843829.	3.5	5
27	Editorial: Novel Small-Molecule Agents in Overcoming Multidrug Resistance in Cancers. <i>Frontiers in Chemistry</i> , 2022, 10, .	3.6	4
28	Therapeutic implication of carbon monoxide in drug resistant cancers. <i>Biochemical Pharmacology</i> , 2022, 201, 115061.	4.4	4
29	Design, Synthesis and Biological Evaluations of Novel Conjugates of Danshensu, Tetramethylpyrazine and Hydrogen Sulfide Donors as Cardioprotective Agents. <i>Asian Journal of Chemistry</i> , 2016, 28, 2555-2561.	0.3	3
30	Navigating Calcium and Reactive Oxygen Species by Natural Flavones for the Treatment of Heart Failure. <i>Frontiers in Pharmacology</i> , 2021, 12, 718496.	3.5	3
31	Paclitaxel and chemoresistance. , 2022, , 251-267.		1
32	BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 13-27.		0
33	Icotinib improves progression free survival in epidermal growth factor receptor positive non-small cell lung cancer patients. <i>Translational Cancer Research</i> , 2018, 7, S26-S30.	1.0	0